Lupin Expands Global Reach With Plasil Licensing Deals

Lupin Ltd, one of India’s leading pharmaceutical companies, has announced new licensing agreements that will expand the reach of its gastroenterology brand Plasil. The company has entered into exclusive partnerships with Neopharmed to market and distribute Plasil in the Philippines and Brazil, two important growth markets for healthcare.  

Key highlights from the announcement include  

• Lupin has signed exclusive licensing agreements with Neopharmed for Plasil.  
• The agreements cover distribution in the Philippines and Brazil, strengthening Lupin’s global presence.  
• Plasil is a gastroenterology brand widely used for treating gastrointestinal disorders.  
• The partnerships will enhance patient access to effective treatments in emerging markets.  
• The deals align with Lupin’s strategy of expanding specialty products internationally.  
• Industry experts note that Brazil and the Philippines are high-potential markets for gastroenterology therapies, offering strong growth opportunities.  

The agreements mark a significant step in Lupin’s global expansion strategy, reinforcing its commitment to delivering innovative and accessible healthcare solutions. By partnering with Neopharmed, Lupin aims to leverage local expertise and ensure wider availability of Plasil in key international markets.  

Sources: Business Standard, Moneycontrol, Economic Times